Why Is Precigen Stock Surging On Friday?
1. FDA approves Precigen's Papzimeos for recurrent respiratory papillomatosis (RRP). 2. Papzimeos is the first FDA-approved treatment for adults with RRP. 3. 51% of patients achieved complete response, lasting over 12 months. 4. Precigen will start promoting Papzimeos immediately following the approval. 5. PGEN stock rose 44.32% to $2.67 in premarket trading.